☆ 4.8 Editorial Material

Targeting HER2-Mutant NSCLC - The Light Is On

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Unlocking the potential of antibody-drug conjugates for cancer therapy

Joshua Z. Drago et al.

Summary: Nine ADCs are currently approved for cancer treatment, with many more in development. Advances in synthetic biochemistry have led to a new generation of ADCs promising improved tissue specificity and cytotoxicity. Despite impressive activity against treatment-refractory cancers, challenges such as systemic toxicity and acquired resistance remain. This review discusses the design, mechanism of action, and limitations of ADCs, proposing strategies to maximize their therapeutic benefit for cancer patients.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates A Review

Paolo Tarantino et al.

Summary: ERBB2-directed antibody-drug conjugates have revolutionized breast cancer treatment and shown promise in other tumors, but recent clinical observations have raised concerns about potential lung toxicity, highlighting the importance of appropriate diagnosis and management strategies.

JAMA ONCOLOGY (2021)

添加到收藏夹

Article Oncology